Canopy Growth (CGC) Cash from Financing Activities (2019 - 2025)
Canopy Growth (CGC) reported Cash from Financing Activities of $204.9 million for Q4 2025, up 1051.17% on a YoY basis from $17.8 million in Q4 2024, and up 1015.35% sequentially from $18.4 million in Q2 2025.
Canopy Growth (CGC) Cash from Financing Activities (2019 - 2025) Analysis & Trends
Canopy Growth (CGC) has 7 years of Cash from Financing Activities data on file, last reported at $204.9 million in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities rose 1051.17% year-over-year to $204.9 million; the trailing twelve-month figure through Dec 2025 stood at $267.0 million (up 109.76% YoY), and the FY2026 full-year result was $242.4 million, up 133.96% from the prior year.
- Cash from Financing Activities rose to $204.9 million in Q4 2025, from $18.4 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $786.6 million in Q1 2021 to a low of -$204.5 million in Q3 2023.
- A 5-year average of $40.7 million and a median of -$273368.7 in 2021 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities slumped 36245.01% in 2022 and surged 14591.67% in 2023, its largest moves.
- Tracing CGC's Cash from Financing Activities over 5 years: stood at $272114.3 in 2021, then plunged by 36245.01% to -$98.4 million in 2022, then jumped by 50.54% to -$48.6 million in 2023, then surged by 55.71% to -$21.5 million in 2024, then surged by 1051.17% to $204.9 million in 2025.
- Business Quant data shows CGC's Cash from Financing Activities at $204.9 million in Q4 2025, $18.4 million in Q2 2025, and -$21.5 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Canopy Growth | 197.77 Mn | -68.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 204.94 Mn |
| Dec 31, 2025 | 204.94 Mn |
| Jun 30, 2025 | 18.37 Mn |
| Jun 30, 2025 | 18.37 Mn |
| Dec 31, 2024 | -21.55 Mn |
| Dec 31, 2024 | -21.55 Mn |
| Sep 30, 2024 | 65.20 Mn |
| Sep 30, 2024 | 65.20 Mn |
| Jun 30, 2024 | 77.34 Mn |
| Jun 30, 2024 | 77.34 Mn |
| Mar 31, 2024 | 6.28 Mn |
| Mar 31, 2024 | 6.28 Mn |
| Dec 31, 2023 | -48.65 Mn |
| Dec 31, 2023 | -48.65 Mn |
| Sep 30, 2023 | -204.53 Mn |
| Sep 30, 2023 | -204.53 Mn |
| Jun 30, 2023 | -99.09 Mn |
| Jun 30, 2023 | -99.09 Mn |
| Mar 31, 2023 | 93.37 Mn |
| Mar 31, 2023 | 93.37 Mn |